SLAMF7

SLAMF7, also known as CD319, is a cell surface glycoprotein belonging to the signaling lymphocytic activation molecule (SLAM) family. It is expressed on a variety of immune cells, including natural killer (NK) cells, T cells, and B cells, as well as on malignant plasma cells in multiple myeloma. SLAMF7 plays a role in cell adhesion, activation, and cytotoxicity. In particular, it is involved in the activation of NK cells and the enhancement of their cytotoxic activity against target cells. Because of its overexpression in multiple myeloma cells, SLAMF7 has become an attractive target for immunotherapy. Therapeutic antibodies targeting SLAMF7 have shown promising results in clinical trials, demonstrating their ability to induce direct tumor cell killing and enhance immune-mediated destruction of myeloma cells. Ongoing research aims to further elucidate the precise signaling pathways mediated by SLAMF7 and to optimize its use in the treatment of hematological malignancies.